- Abstract:
-
Plasmodium vivax is the world's most widely distributed malaria parasite and a potential cause of morbidity and mortality for approximately 2.85 billion people living mainly in Southeast Asia and Latin America. Despite this dramatic burden, very few vaccines have been assessed in humans. The clinically relevant vectors modified vaccinia virus Ankara (MVA) and the chimpanzee adenovirus ChAd63 are promising delivery systems for malaria vaccines due to their safety profiles and proven ability to...
Expand abstract - Publication status:
- Published
- Journal:
- Infection and immunity
- Volume:
- 82
- Issue:
- 3
- Pages:
- 1277-1286
- Publication date:
- 2014-03-05
- DOI:
- EISSN:
-
1098-5522
- ISSN:
-
0019-9567
- URN:
-
uuid:8cb71f44-1133-44db-add8-41a61be50882
- Source identifiers:
-
445794
- Local pid:
- pubs:445794
- Language:
- English
- Keywords:
- Copyright date:
- 2014
Journal article
Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record